Viatris Secures Japan Approval for WAKIX, Expanding Sleep Disorder Portfolio — Viatris Inc.

Event summary

Viatris' WAKIX (pitolisant) approved in Japan for narcolepsy and obstructive sleep apnea syndrome (OSAS)-related excessive daytime sleepiness (EDS).
First histamine H3 receptor antagonist/inverse agonist approved for these indications in Japan.
Approval supported by domestic Phase 3 trials and international studies.
WAKIX licensed exclusively to Viatris for the Japan market, discovered by Bioprojet.
Not classified as a controlled substance, designated as an orphan drug in Japan for narcolepsy.

The big picture

Viatris' approval of WAKIX in Japan addresses a significant unmet medical need in sleep medicine, particularly for narcolepsy and OSAS-related EDS. This expansion strengthens Viatris' innovative portfolio in a strategically important market, where sleep disorders are prevalent but treatment options remain limited. The approval also underscores Viatris' focus on differentiated therapies, positioning the company to capture market share in Japan's growing healthcare sector.

What we're watching

Market Penetration: How Viatris will position WAKIX against existing treatments in Japan's competitive sleep disorder market.
Revenue Impact: Whether the approval will drive meaningful revenue growth in Viatris' Japan operations.
Regulatory Strategy: The pace at which Viatris can secure additional approvals for WAKIX in other high-potential markets.